Number of shares and votes in Active Biotech

(Thomson Reuters ONE) -


The number of shares and votes in Active Biotech has changed as a result ofthe
exercise of employee stock options.

Today, the last trading day of the month, there are in total 64,175,530 shares
and votes in Active Biotech.


Lund, March 31, 2010
Active Biotech AB (publ)


For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam(at)activebiotech.com


Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 am CET on March 31, 2010.



[HUG#1399855]





Press release (PDF): http://hugin.info/1002/R/1399855/355268.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 31.03.2010 - 16:01 Uhr
Sprache: Deutsch
News-ID 18470
Anzahl Zeichen: 0

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 265 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Number of shares and votes in Active Biotech"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech